No abstract

No abstract

No abstract

No abstract

In this work, a novel approach was developed to prepare an engineered biochar from KMnO4 treated hickory wood through slow pyrolysis (600°C). Characterization experiments with various tools showed that the engineered biochar surface was covered with MnOx ultrafine particles. In comparison to the pristine biochar, the engineered biochar also had more surface oxygen-containing functional groups and much larger surface area. Batch sorption experiments showed that the engineered biochar had strong sorption ability to Pb(II), Cu(II), and Cd(II) with maximum sorption capacities of 153.1, 34.2, and 28.1mg/g, respectively, which were significantly higher than that of the pristine biochar. Batch sorption experiments also showed that the dosage, initial solution pH, and ionic strength affected the removal of the heavy metals by the biochars. The removal of the metals by the engineered biochar was mainly through surface adsorption mechanisms involving both the surface MnOx particles and oxygen-containing groups.

No abstract

The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound 2 is a phase 1 clinical trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized molecular modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clinical candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA.

No abstract